Low-intensity apixaban was not judged less effective than full-intensity apixaban and resulted in fewer clinically relevant bleeding events.
Patients with cancer-associated venous thromboembolism (VTE) are at increased risk for recurrent events, warranting long-term anticoagulation in many individuals. However, these patients also have a substantive risk for bleeding events in the context of cancer and continued anticoagulation. Although low-intensity anticoagulation has been successfully tested and brought into practice in noncancer settings (JAMA Cardiol 2022; 7:747 and N Engl J Med 2013; 368:699), its safety and efficacy for secondary prevention of VTE in patients with cancer remains unclear.
In an industry-funded, double-blind, randomized, noninferiority trial (with a prespecified hazard ratio noninferiority margin of 2), the investigators enrolled 1766 patients with cancer-a…
Reviewing Author
DisclosuresGrant/Research SupportBrigham and Women’s Hospital; American Heart Association and VIVA Physicians
Editorial BoardsThrombosis Research; Thrombosis and Haemostasis; Journal of the American College of Cardiology
Leadership Positions in Professional SocietiesSociety for Vascular Medicine (Research, Quality, and Publications Committee member); International Society on Thrombosis and Haemostasis
DisclosuresGrant/Research SupportBrigham and Women’s Hospital; American Heart Association and VIVA Physicians
Editorial BoardsThrombosis Research; Thrombosis and Haemostasis; Journal of the American College of Cardiology
Leadership Positions in Professional SocietiesSociety for Vascular Medicine (Research, Quality, and Publications Committee member); International Society on Thrombosis and Haemostasis